68Ga-Edotreotide, distributed under the brand name TOCscan® (Sogacin® in Austria/ France), is the companion diagnostic in ITM´s theranostic approach for the treatment of neuroendocrine tumors (NETs). This ready-to-use radiopharmaceutical is registered in Germany, France, and Austria and is used to diagnose NETs and localize metastases throughout the body.
TOCscan® contains the targeting molecule Edotreotide (DOTATOC), an octreotide-derived somatostatin analogue, labeled with the medical radioisotope Gallium-68 (68Ga). Edotreotide contains DOTA, which functions as a chelator for radioisotopes, and TOC, a synthetic somatostatin receptor agonist. It binds with high affinity to somatostatin receptors and retains both its receptor binding properties and its physiological function when labeled with 68Ga. Somatostatin receptors are predominantly overexpressed by neuroendocrine tumors. TOCscan®, upon binding to SST receptors in vivo, is internalized and retained by tumor cells.
TOCscan® is used for PET or PET/CT molecular imaging of neuroendocrine tumors (NETs). As well as for diagnosis and staging of NETs, TOCscan® imaging is used for therapy planning and dosimetry in preparation for n.c.a. 177Lu-Edotreotide (Solucin®) therapy. Solucin®, ITM´s therapeutic radiopharmaceutical for NETs, is currently in the phase III clinical trial, COMPETE. Together, Solucin® and TOCscan® act as an excellent theranostic pair for the diagnosis and treatment of NETs.